Diagnosing nephrogenic systemic fibrosis in the post-FDA restriction era

Thomson, L. K., Thomson, P. C., Kingsmore, D. B., Blessing, K., Daly, C. D., Cowper, S. E. and Roditi, G. H. (2015) Diagnosing nephrogenic systemic fibrosis in the post-FDA restriction era. Journal of Magnetic Resonance Imaging, 41(5), pp. 1268-1271. (doi: 10.1002/jmri.24664) (PMID:24903851)

Full text not currently available from Enlighten.

Abstract

The emergence of an association between gadolinium-based contrast agents (GBCA) and the rare condition nephrogenic systemic fibrosis (NSF) led to a warning in 2006 from the Food and Drug Administration (FDA) restricting the use of the GBCAs to patients with an estimated glomerular filtration rate of >30 mL/min/1.73m2. We discuss our experience with a post-FDA restriction presentation of NSF and subsequent patient death in which the prolonged lead-time of ∼5.5 years led to challenges in ensuring a secure diagnosis of NSF and establishing risk exposures. Accurate contemporary records of contrast administration and clinical factors alongside clinical and pathological expertise ensured that we were able to confidently diagnose NSF, despite the length of lead time and confounding factors.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Thomson, Dr Peter and Roditi, Dr Giles and Kingsmore, Professor David
Authors: Thomson, L. K., Thomson, P. C., Kingsmore, D. B., Blessing, K., Daly, C. D., Cowper, S. E., and Roditi, G. H.
College/School:College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing
Journal Name:Journal of Magnetic Resonance Imaging
Publisher:Wiley Periodicals, Inc.
ISSN:1053-1807
ISSN (Online):1522-2586

University Staff: Request a correction | Enlighten Editors: Update this record